-
PROVIDERS
Register now
Are you getting the full picture? A webinar series on the power of comprehensive intelligent diagnostics
-
LIFE SCIENCES
Enroll now
Tempus’ Patient-Derived Organoid ScreensEvaluate the efficacy of your preclinical compounds using fixed organoid panels designed for diverse therapeutic applications. Space is limited — enroll by June 30, 2025, to secure your spot.
-
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
- INVESTORS
CARE GAP CLOSURE
Tempus Next Oncology
An AI-enabled care pathway platform that empowers oncology providers to deliver the Next step in a patient’s care journey.
Our Solution
Tempus Next: AI-enabled care pathway intelligence
With Tempus Next’s bi-directional site integrations and near real time data feed, life sciences teams can access current, comprehensive, and actionable patient-journey insights based on de-identified patient records. Tempus Next proactively surfaces care gaps, allowing teams to assess impact in near real-time and plan additional educational campaigns.
Identify and contextualize patients in their care journey
Tempus Next is designed to surface deep patient journey insights from multimodal, longitudinal patient data including medical imaging data, EHR data, lab results, pathology reports, and clinician notes.
Monitor barriers to precision medicine adoption
Next delivers de-identified institution-level insights reports that track testing rates, treatment patterns, and reasons for deviations from guideline-directed care over time to life sciences and hospital systems.
Increase equitable access to care
Next helps ensure timely and accurate diagnostics, procedures and therapies for all patients, regardless of socioeconomic status.
Figure: In this study, black patients saw a larger decrease in average time from index echo to follow up (120 vs 64 days) compared to white patients (57 to 36 days), showing the improvement in black patients’ time to follow up towards the average seen in white patients’ (narrowing the gap).
Horde G, Sotelo M, D’Amico A, et al. Use of an echocardiographic-based, artificial intelligence system to improve racial disparities in care of patients with valvular heart disease. European Heart Journal – Cardiovascular Imaging. 2023;24(Suppl 1):38.3.
Using AI to identify and close gaps in care for cancer patients
Learn how TriHealth Cancer and Blood institute implemented Tempus Next to accelerate the adoption of precision care pathways for NSCLC patients.
Watch our webinar and read our Q&A recapCase Study
Closing the biomarker testing gap for early stage NSCLC (Non-small cell lung cancer) patients with Tempus NextLearn how Tempus Next was deployed at TriHealth Cancer and Blood Institute in Cincinnati, Ohio to surface and close gaps in biomarker testing for NSCLC patients.
LEARN MORE
Case Study
An algorithmic approach to close care gaps for patients that may benefit from confirmatory IHC HER2 testingLearn how Tempus, in partnership with a global pharmaceutical company, deployed a HER2 predictive algorithm at selected sites within the Tempus network to identify patients who may benefit from additional confirmatory IHC HER2 testing.
LEARN MORE
Improve adherence to clinical guidelines through AI-enabled and targeted notifications at the point of care.
This is data-driven precision medicine
This is the future of healthcare.